Global Cancer Antibody Combinations Market Opportunity and Clinical Trials Insight 2028

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Global Cancer Antibody Combinations Market Opportunity and Clinical Trials Insight 2028 Report Findings and Highlights:

Global Cancer Antibody Combinations Market Opportunity: > USD 50 Billion By 2028
Insight On Approved Cancer Antibody Combinations In Market: > 65 Antibodies Combinations
Insight On Cancer Antibody Combinations In Clinical Trials: > 490 Antibodies Combinations
Patent, Pricing, and Dosage Insight On Approved Combinations
Global Cancer Antibody Combinations Clinical Trials Insight By Company, Indication and Phase
Global Antibody Combinations Market Development by Region and Indications

Combinations Included In Report:

Approved Antibody - Antibody Combinations
Approved Antibody - Small Molecule Inhibitors Combinations
Approved Antibody - Immunomodulatory Agents Combinations
Approved Antibody - Chemotherapy Combinations
Approved Antibody - Mixed Combinations
Ongoing Clinical Trials Combination With Bispecific Antibodies, Cancer Vaccines, Cell Therapies, Radiotherapy

In the recent years, the landscape of medical therapeutics has witnessed a paradigm shift with the emergence of antibody combination therapies, a dynamic approach that intertwines the precision of antibodies to target specific molecules with the synergistic benefits of different types of antibodies. By merging different types of monoclonal antibodies with other therapeutic agents, numerous pathways that are involved in the pathogenesis of cancer may be targeted simultaneously, thereby, possibly leading to additive or else synergistic effects. Theoretically, the combinations of antibodies are very suitable approach that can be employed for the treatment of cancer modalities because of the fact that the antibody combination therapy aids to limit overlapping toxicity along with lack of pharmacokinetic (PK) interactions.

The hypothesis of combining antibodies with other therapeutic agents began in the late 1990s when the researchers together with scientists amplified the preclinical testing that includes a combinations of monoclonal antibodies (mAb) with chemotherapy, radiotherapy or any other therapeutic agents in order to address the occurrence of drug resistant strains or the escape mechanism for observed in cancer malignancies. The main purpose of these investigations was to expand the therapeutic index as well as the potential of mAbs. Advantages such as amended efficiency, diminished toxicities, delayed development of therapy or drug resistances in addition dose reduction were observed in the preclinical studies that come along with antibody combinations.

In dichotomy with the conventional treatments such as chemotherapy and radiotherapy, which clenches the possibility to damage healthy cells, with the arrival of antibody combination therapies has transformed the landscape of targeted medicine. As of now, multiple antibody combination therapies such as Phesgo, Herceptin with Perjeta, Ramucirumab with docetaxel, atezolizumab, Bevacizumab with chemotherapy, atezolizumab and bevacizumab, and ipilimumab and nivolumab etc have been approved by the FDA, EMA, NICE and others for the treatment of diverse type of cancers.

In the realm of cancer therapy, the preliminary clinical development for the domain of antibody combinations were focused on creating anti-PD-1, anti-CTLA-4 and anti-PD-L1 monoclonal antibody (mAb) combinations, there has been modern improvement observed in harnessing the potential of mAb in conjugation with chemotherapy or with various oral small molecule multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) or platelet derived growth factor receptor (PDGFR) as the first-line treatment for multiple types of cancer like advanced solid tumors, hematological cancer, etc. Zhejiang University based in China is conducting clinical studies in which the combination of anti-PD-1 antibody with Donafenib, multikinase inhibitor, is ongoing to evaluate the safety and efficacy of the treatment regimen.

Another pharmaceutical company based in China, Chia Tai Tianqing Pharmaceutical Group reported another combination of anti-PD-1 antibody, Penpulimab with multi targeted receptor TKI, Anlotinib for the treatment of patients suffering from hepatocellular cancer (HCC). The primary goal of this study is to assess the effectiveness of combined treatment regimen for adjuvant therapy. It is a randomized, double-blind, placebo-controlled, multicenter phase 3 study which was initiated in May 2023 and is expected to be complete by December 2026.

Hitherto, the clinical pipeline for the domain of antibody combination therapy for treating cancer modalities majorly consists of immune checkpoint inhibitors, such as CTLA-4, PD-1 and PD-L1, PP2A inhibitors, CDK4/6 inhibitors, mAbs targeting HER 2, TIGIT mAbs, bispecific antibodies, CAR T cell therapies, antibody drug conjugates, and others. It is expected that the imminent years will certainly witness innovative antibody combinations for the treatment of cancer malignancies as evident from augmenting interest in pharmaceutical sectors and fostering FDA designations to novel combination therapy. For instance, in August 2023, Agenus was granted the Fast Track Designation for its innovative antibody combination, botensilimab (AGEN1181) and balstilimab (AGEN2034) for the treatment of colorectal cancer patients.

With the increasing prevalence of cancer types at an alarming gait urges the need to develop better as well as innovative antibody combination therapies which could provide cure in addition to anticipation amidst the populace suffering from cancer across the globe. Furthermore, an inclining market trend towards utilizing the realm of antibody combination has been observed due to involvement of various stakeholders from pharmaceutical and biotech companies such as Pfizer, Bristol-Myers Squibb, AstraZeneca, Daiichi Sankyo, Taizhou EOC Pharma, Agenus, Novartis, Celldex Therapeutics and Merck. With the current market scenario, the future of the antibody combination market looks promising and is expected to multiple further as evident from the growing clinical trials, rising research and development and involvement of various stakeholders in the domain.

Introduction to Cancer Antibody Combinations

1.1 History, Development and Evolution

1.2 Approved Cancer Antibody Combinations

Need of Antibody Combinations

Global Cancer Antibody Combinations Market and Clinical Development Insight

3.1 Current Market Scenario

3.2 Future Outlook

Global Antibody Combinations Market Insight by Region

4.1 US

4.2 China

4.3 Europe

4.4 Japan

4.5 UK

4.6 Canada

4.7 South Korea

Global Cancer Antibody Combinations Clinical Trials Overview

5.1 By Antibody Classification

5.2 By Breakthrough Therapy and Fast Track Status

5.3 By Company

5.4 By Country

5.5 By Indication

5.6 By Phase

Global Antibody Combinations Market Insight by Indication

6.1 Lung Cancer

6.2 Melanoma

6.3 Breast Cancer

6.4 Hepatocellular Cancer

6.5 Colorectal Cancer

6.6 Renal Cell Carcinoma

6.7 Lymphoma

6.8 Leukemia

6.9 Multiple Myeloma

Global Cancer Antibody Combinations Clinical Trials Insight By Company, Indication and Phase

7.1 Research

7.2 Preclinical

7.3 Phase-I

7.4 Phase-I/II

7.5 Phase-II

7.6 Phase-II/III

7.7 Phase-III

7.8 Preregistration

7.9 Registered

Approved/Marketed Cancer Antibody Combinations Clinical Trials Insight By Company, Country and Indication

Antibody - Antibody Combinations – Pricing, Patent and Dosing Insight

9.1 Opdivo + Yervoy

9.1.1 Overview and Patent Insight

9.1.2 Pricing and Dosage Insight

9.2 Opdualag (nivolumab and relatlimab)

9.2.1 Overview and Patent Insight

9.2.2 Pricing and Dosage Insight

9.3 Imjudo + Imfinzi

9.3.1 Overview and Patent Insight

9.3.2 Pricing and Dosage Insight

Deatiled Combinations Are Mentioned in Report Sample

Antibody - Small Molecule Inhibitors Combinations – Pricing, Patent and Dosing Insight

10.1 Gazyva + Imbruvica

10.1.1 Overview and Patent Insight

10.1.2 Pricing and Dosage Insight

10.2 Imbruvica + Rituximab

10.2.1 Overview and Patent Insight

10.2.2 Pricing and Dosage Insight

10.3 Bavencio + Inlyta

10.3.1 Overview and Patent Insight

10.3.2 Pricing and Dosage Insight

Deatiled Combinations Are Mentioned in Report Sample

Antibody - Immunomodulatory Agents Combinations – Pricing, Patent and Dosing Insight

11.1 Monjuvi + lenalidomide

11.1.1 Overview and Patent Insight

11.1.2 Pricing and Dosage Insight

11.2 Avastin + Interferon-alfa

11.2.1 Overview and Patent Insight

11.2.2 Pricing and Dosage Insight

Antibody - Chemotherapy Combinations – Pricing, Patent and Dosing Insight

12.1 Jemperli

12.1.1 Overview and Patent Insight

12.1.2 Pricing and Dosage Insight

12.2 Cyramza

12.2.1 Overview and Patent Insight

12.2.2 Pricing and Dosage Insight

12.3 Portrazza

12.3.1 Overview and Patent Insight

12.3.2 Pricing and Dosage Insight

Deatiled Combinations Are Mentioned in Report Sample

Antibody - Mixed Combinations

13.1 Phesgo (Perjeta + Herceptin + hyaluronidase)

13.1.1 Overview and Patent Insight

13.1.2 Pricing and Dosage Insight

13.2 Darzalex

13.2.1 Overview and Patent Insight

13.2.2 Pricing and Dosage Insight

13.3 Empliciti

13.3.1 Overview and Patent Insight

13.3.2 Pricing and Dosage Insight

Deatiled Combinations Are Mentioned in Report Sample

Competitive Landscape

14.1 AbbVie

14.2 Adagene

14.3 Agenus

14.4 Akeso Biopharma

14.5 Amgen

14.6 AstraZeneca

14.7 BeiGene

14.8 Biocad

14.9 BioInvent International

14.10 Bio-Thera Solutions

14.11 Boehringer Ingelheim

14.12 Bristol-Myers Squibb

14.13 Concentra Biosciences

14.14 Daiichi Sankyo Company

14.15 Eli Lilly and Company

14.16 Eucure Biopharma

14.17 Genentech

14.18 Genmab

14.19 GSK

14.20 ImmunoGen

14.21 Innovent Biologics

14.22 Janssen Research and Development

14.23 Jiangsu Hengrui Medicine Co.

14.24 LaNova Medicines Limited

14.25 Lepu Biopharma

14.26 MacroGenics

14.27 Merck

14.28 Merus

14.29 NGM Biopharmaceuticals

14.30 Novartis

14.31 Pfizer

14.32 Regeneron Pharmaceuticals

14.33 Roche

14.34 Seagen

14.35 Shanghai Henlius Biotech

14.36 Shanghai Junshi Biosciences

14.37 Sinocelltech

14.38 Symphogen

14.39 UCB

14.40 Xencor

Figure 1-1: Developmental Milestones for Antibody Combinations

Figure 2-1: Comparison of Conventional Therapies v/s Antibody Combination

Therapy

Figure 2-2: Need of Antibody Combinations

Figure 2-3: Different Combinations of Antibodies with Other Therapeutic Agents

Figure 2-4: Expected Antibody Combinations

Figure 3-1: Global – Cancer Antibody Combination Market Opportunity (US$ Billion),

2023 - 2028

Figure 3-2: Antibody Combination Market - Prominent Regions

Figure 3-3: Aspects of Current Antibody Combinations Market

Figure 3-4: Future Characteristics of Antibody Combinations Market

Figure 4-1: COMBI-i Phase III Study – Initiation and Completion Years

Figure 4-2: CONTACT-01 Phase III Study – Initiation and Completion Years

Figure 4-3: NCT05800015 Phase II//III Study – Initiation and Completion Years

Figure 4-4: MagnetisMM-4 Phase II Study – Initiation and Completion Years

Figure 4-5: DREAMM 6 Phase I/II Study – Initiation and Completion Years

Figure 4-6: NCT04421352 Phase I Study – Initiation and Completion Year

Figure 4-7: NCT05867121 Phase I Study – Initiation and Completion Year

Figure 4-8: NCT06054477 Phase I/II Study – Initiation and Completion Year

Figure 4-9: NCT04868877 Phase I/II Study – Initiation and Completion Year

Figure 4-10: NCT05867121 Phase I Study – Initiation and Completion Year

Figure 4-11: NCT06038578 Phase II Study – Initiation and Completion Year

Figure 4-12: DESTINY-Breast01 Phase II Study – Initiation and Completion Year

Figure 4-13: BI-1607 and Trastuzumab Phase I/II Study – Initiation and Completion Year

Figure 4-14: Myechild01 Phase III Study – Initiation and Completion Year

Figure 4-15: GS-9911 and Zimberelimab Phase I Study – Initiation and Completion Year

Figure 4-16: EGIA-002 Phase II Study – Initiation and Completion Year

Figure 4-17: TUC1PI-01 Phase I/II Study – Initiation and Completion Year

Figure 4-18: TUC1PI-01 Phase I/II Study – Initiation and Completion Year

Figure 4-19: LEAP-008 Phase III Study – Initiation and Completion Year

Figure 4-20: VOLGA Phase III Study – Initiation and Completion Year

Figure 4-21: MarkV-01 Phase I Study – Initiation and Completion Year

Figure 5-1: Global – Cancer Antibody Combinations Clinical Trials By Antibody

Classification, 2023 till 2028

Figure 5-2: Global – Cancer Antibody Combinations Clinical Trials By Priority Status,

2023 till 2028

Figure 5-3: Global – Cancer Antibody Combinations Clinical Trials By Company, 2023

till 2028

Figure 5-4: Global – Cancer Antibody Combinations Clinical Trials By Country, 2023

till 2028

Figure 5-5: Global – Cancer Antibody Combinations Clinical Trials By Indication, 2023

till 2028

Figure 5-6: Global – Cancer Antibody Combinations Clinical Trials By Phase, 2023 till

2028

Figure 6-1: Lung Cancer – Approved Antibody Combinations

Figure 6-2: Cemiplimab and Fianlimab Phase II/III Study – Initiation and Completion Year

Figure 6-3: Daratumumab, Nivolumab and KRAS vaccine Phase II Study – Initiation and

Completion Year

Figure 6-4: Lung Cancer - Clinical Pipeline of Antibody Combinations

Figure 6-5: Melanoma – Approved Antibody Combinations

Figure 6-6: NCT05608291 Phase III Study – Initiation and Completion Year

Figure 6-7: OrienX010-II-11 Phase I Study – Initiation and Completion Year

Figure 6-8: MM1636 Phase I/II Study – Initiation and Completion Year

Figure 6-9: Breast Cancer - Approved Antibody Combinations

Figure 6-10: Trastuzumab and Pyrotinib Phase III Study – Initiation and Completion Year

Figure 6-11: Inetetamab, Toripalimab and Paclitaxel Phase IV Study – Initiation and

Completion Year

Figure 6-12: Breast Cancer – Key Player in Antibody Combination Commercial Market

Figure 6-13: Breast Cancer – Different Antibody Combination With Other

Therapeutic Agents

Figure 6-14: Hepatocellular Cancer– Approved Antibody Combinations

Figure 6-15: Combination of Antibody with DEB-TACE to Treat Hepatocellular

Carcinoma

Figure 6-16: Penpulimab and Anlotinib Phase III Study – Initiation and Completion Year

Figure 6-17: Collaboration of XNK Therapeutics with Global Pharma Company

Figure 6-18: Antibody Combinations - Benefits to treat Colorectal Cancer

Figure 6-19: NCT06099951 Phase II Study – Initiation and Completion Year

Figure 6-20: KEYFORM-007 Phase III Study – Initiation and Completion Year

Figure 6-21: Renal Cell Carcinoma – Approved Antibody Combinations

Figure 6-22: SillaJen and Regeneron Pharmaceuticals – Novel Approach of Combining

Oncolytic Vaccinia Virus to Treat Renal Cell Carcinoma

Figure 6-23: BMC128 and Nivolumab Phase I Study – Initiation and Completion Year

Figure 6-24: Lymphoma – Approved Antibody Combinations

Figure 6-25: NCT04464798 Phase I Study – Initiation and Completion Year

Figure 6-26: Odronextamab, Lenalidomide and Rituximab Phase III Study – Initiation and

Completion Year

Figure 6-27: L-DEP and PD-1 Antibody Phase III Study – Initiation and Completion Year

Figure 6-28: Collaboration of MorphoSys and Incyte, IGM Bioscience and ADC

Therapeutic, 2022

Figure 6-29: Leukemia – Approved Antibody Combinations

Figure 6-30: NCT06043674 Phase II Study – Initiation and Completion Year

Figure 6-31: NP137, Venetoclax and Azacitidine Phase I/II Study – Initiation and

Completion Year

Figure 6-32: Novartis – Hypothesis for Phase 3 Clinical Study

Figure 6-33: Sabatolimab and Azacitidine Phase III Study – Initiation and Completion

Year

Figure 6-34: Multiple Myeloma – Approved Antibody Combinations

Figure 6-35: NCT05730036 Phase III Study – Initiation and Completion Year

Figure 6-36: Pharmaceutical Companies Conducting Phase 3 Studies for Multiple

Myeloma

Figure 6-37: NCT05363111 Phase I Study – Initiation and Completion Year

Figure 9-1: Opdivo and Yervoy – Minimum Market Exclusivity Year by Region

Figure 9-2: Opdivo and Yervoy – FDA Approval Years by Indications

Figure 9-3: Opdivo and Yervoy – EMA Approval Years by Indications

Figure 9-4: US – Opdivo Cost per Unit and Supply (US$), December’2023

Figure 9-5: US – Yervoy Cost per Unit and Supply (US$), December’2023

Figure 9-6: EU – Opdivo Cost of Supply (US$), November’2023

Figure 9-7: EU – Yervoy Cost of Supply (US$), November’2023

Figure 9-8: Opdualag – Approval Years by Region

Figure 9-9: Opdualag – Minimum Market Exclusivity Year by Region

Figure 9-10: US and EU – Opdualag Cost per Supply (US$), November’2023

Figure 9-11: Imfinzi and Imjudo – Patent Expiry Years by Region

Figure 9-12: US – Imfinzi Cost per Unit and Supply (US$), November’2023

Figure 9-13: US – Imjudo Cost per Unit and Supply (US$), November’2023

Figure 9-14: EU – Imfinzi Cost per Unit and Supply (US$), November’2023

Figure 9-15: EU – Imjudo Cost per Unit and Supply (US$), November’2023

Figure 9-16: US – Keytruda Cost per Unit and Supply (US$), November’2023

Figure 9-17: US – Padcev Cost per Unit and Supply (US$), November’2023

Figure 9-18: EU – Keytruda Cost per Unit and Supply (US$), November’2023

Figure 9-19: EU – Padcev Cost per Unit and Supply (US$), November’2023

Figure 9-20: US – Keytruda Cost per Unit and Supply (US$), November’2023

Figure 9-21: US – Herceptin Cost per Unit and Supply (US$), November’2023

Figure 9-22: US – Trastuzumab Biosimilar Cost per Unit and Supply (US$),

November’2023

Figure 9-23: EU – Keytruda Cost per Unit and Supply (US$), November’2023

Figure 9-24: US – Tecentriq Cost per Unit and Supply (US$), November’2023

Figure 9-25: US – Avastin Cost per Unit and Supply (US$), November’2023

Figure 9-26: US – Bevacizumab Biosimilar Cost per Unit and Supply for 4ml (US$),

November’2023

Figure 9-27: US – Bevacizumab Biosimilar Cost per Unit and Supply for 16ml (US$),

November’2023

Figure 9-28: US – Bevacizumab Biosimilar Alymsys Cost per Unit and Supply for 40ml and

160ml (US$), November’2023

Figure 9-29: EU – Tecentriq Cost per Unit and Supply (US$), November’2023

Figure 9-30: EU – Bevacizumab Biosimilar Vegzelma Cost per Supply (US$),

November’2023

Figure 9-31: US – Perjeta Cost per Unit and Supply (US$), November’2023

Figure 9-32: US – Herceptin Cost per Unit and Supply (US$), November’2023

Figure 9-33: US – Trastuzumab Biosimilar Cost per Unit and Supply (US$),

November’2023

Figure 9-34: EU – Perjeta Cost per Supply (US$), November’2023

Figure 9-35: US – Polivy Cost per Supply (US$), November’2023

Figure 9-36: US – Rituxan Cost per Unit and Supply (US$), November’2023

Figure 9-37: US – Rituximab Biosimilar Cost per Unit and Supply of 10ml (US$),

November’2023

Figure 9-38: US – Rituximab Biosimilar Cost per Unit and Supply of 50ml (US$),

November’2023

Figure 9-39: EU – Polivy Cost per Supply (US$), November’2023

Figure 9-40: EU – Rituximab Biosimilar Truxima Cost per Supply (US$),

November’2023

Figure 10-1: US – Imbruvica Cost per Unit and Supply of 70mg (US$), November’2023

Figure 10-2: US – Imbruvica Cost per Unit and Supply of 140mg (US$), November’2023

Figure 10-3: US – Gazyva Cost per Unit and Supply (US$), November’2023

Figure 10-4: US – Imbruvica Cost per Unit and Supply of 70mg (US$), November’2023

Figure 10-5: US – Imbruvica Cost per Unit and Supply of 140mg (US$), November’2023

Figure 10-6: US – Rituxan Cost per Unit and Supply (US$), November’2023

Figure 10-7: US – Rituximab Biosimilar Cost per Unit and Supply of 10ml (US$),

November’2023

Figure 10-8: US – Rituximab Biosimilar Cost per Unit and Supply of 50ml (US$),

November’2023

Figure 10-9: EU – Rituximab Biosimilar Truxima Cost per Supply (US$),

November’2023

Figure 10-10: US – Bavencio Cost per Unit and Supply (US$), November’2023

Figure 10-11: US – Inlyta Cost per Unit and Supply (US$), November’2023

Figure 10-12: EU – Bavencio Cost per Unit and Supply (US$), November’2023

Figure 10-13: EU – Inlyta Cost per Unit and Supply (US$), November’2023

Figure 10-14: US – Keytruda Cost per Unit and Supply (US$), November’2023

Figure 10-15: US – Inlyta Cost per Unit and Supply (US$), November’2023

Figure 10-16: EU – Keytruda Cost per Unit and Supply (US$), November’2023

Figure 10-17: EU – Inlyta Cost per Unit and Supply (US$), November’2023

Figure 10-18: US – Cyramza Cost per Unit and Supply (US$), December’2023

Figure 10-19: US – Tarceva Cost per Supply (US$), December’2023

Figure 10-20: EU – Cyramza Cost per Unit and Supply (US$), December’2023

Figure 10-21: US – Keytruda Cost per Unit and Supply (US$), November’2023

Figure 10-22: US – Lenvima Cost per Unit and Supply (US$), November’2023

Figure 10-23: EU – Keytruda Cost per Unit and Supply (US$), December’2023

Figure 10-24: US – Opdivo Cost per Unit and Supply (US$), November’2023

Figure 10-25: US – Cabometyx Cost per Unit and Supply (US$), November’2023

Figure 10-26: EU – Opdivo Cost per Unit and Supply (US$), November’2023

Figure 10-27: EU – Cabometyx Cost per Unit and Supply (US$), November’2023

Figure 11-1: US – Monjuvi Cost of Supply (US$), December’2023

Figure 11-2: US – Revlimid Cost per Unit and Supply (US$), December’2023

Figure 11-3: US – Avastin Cost per Unit and Supply (US$), December’2023

Figure 11-4: US – Bevacizumab Biosimilar Cost per Unit and Supply for 4ml (US$),

December’2023

Figure 11-5: US – Bevacizumab Biosimilar Cost per Unit and Supply for 16ml (US$),

December’2023

Figure 11-6: US – Bevacizumab Biosimilar Alymsys Cost per Unit and Supply for 40ml and

160ml (US$), December’2023

Figure 11-7: EU – Bevacizumab Biosimilar Vegzelma Cost per Supply (US$),

December’2023

Figure 12-1: US and EU – Jemperli Cost of Supply (US$), December’2023

Figure 12-2: US – Paclitaxel Cost per Unit and Supply (US$), December’2023

Figure 12-3: US – Paraplatin Cost per Unit and Supply (US$), December’2023

Figure 12-4: US – Carboplatin Cost per Unit and Supply (US$), December’2023

Figure 12-5: US – Cyramza Cost per Unit and Supply (US$), December’2023

Figure 12-6: EU – Cyramza Cost per Unit and Supply (US$), December’2023

Figure 12-7: US – Taxotere Cost per Unit and Supply (US$), December’2023

Figure 12-8: US – Paclitaxel Cost per Unit and Supply (US$), December’2023

Figure 12-9: US and EU – Cyramza Cost per Unit and Supply (US$), December’2023

Figure 12-10: US – Gemzar Cost of Supply (US$), December’2023

Figure 12-11: US – Infugem Cost per Unit and Supply (US$), December’2023

Figure 12-12: US – Cisplatin Cost per Unit and Supply for Intravenous Solution (US$),

December’2023

Figure 12-13: US – Vectibix Cost per Unit and Supply (US$), December’2023

Figure 12-14: US – Eloxatin Cost per Unit and Supply (US$), December’2023

Figure 12-15: US – Oxaliplatin Cost per Unit and Supply of Intravenous Powder (US$),

December’2023

Figure 12-16: US – Oxaliplatin Cost per Unit and Supply of Intravenous Solution (US$),

December’2023

Figure 12-17: US – Adrucil Cost per Unit and Supply (US$), December’2023

Figure 12-18: US – Fluorouracil Cost per Unit and Supply (US$), December’2023

Figure 12-19: US – Cyclophosphamide Cost of Supply of Intravenous Powder (US$),

December’2023

Figure 12-20: US – Cyclophosphamide Cost per Unit and Supply of Intravenous

Solutions of Doses 1g/2ml, 2g/4ml, and 500mg/ml (US$), December’2023

Figure 12-21: US – Cyclophosphamide Cost per Unit and Supply of Intravenous

Solutions of Dose 200mg/ml (US$), December’2023

Figure 12-22: US – Cyclophosphamide Cost per Unit and Supply of Oral Capsule (US$),

December’2023

Figure 12-23: US – Cyclophosphamide Cost per Unit and Supply of Oral Tablet (US$),

December’2023

Figure 12-24: US – Adriamycin Cost of Supply of Intravenous Powder (US$),

December’2023

Figure 12-25: US – Adriamycin Cost per Unit and Supply of Intravenous Solution (US$),

December’2023

Figure 12-26: US – Doxorubicin Cost of Supply of Intravenous Powder (US$),

December’2023

Figure 12-27: US – Doxorubicin Cost per Unit and Supply of Intravenous Solution (US$),

December’2023

Figure 12-28: US – Vincristine Cost per Unit and Supply of Intravenous Solution (US$),

December’2023

Figure 12-29: US – Toposar Cost per Unit and Supply of Intravenous Solution (US$),

December’2023

Figure 12-30: US – Etoposide Cost per Unit and Supply of Intravenous Solution (US$),

December’2023

Figure 12-31: US – Etoposide Cost per Unit and Supply of Oral Capsule (US$),

December’2023

Figure 12-32: US – Prednisone Cost per Unit and Supply of 1mg/ml Oral Solution (US$),

December’2023

Figure 12-33: US – Prednisone Cost per Unit and Supply of 5mg/ml Oral Solution (US$),

December’2023

Figure 12-34: US – Prednisone Cost per Unit and Supply of 1mg Oral Tablet (US$),

December’2023

Figure 12-35: US – Prednisone Cost per Unit and Supply of 2.5mg Oral Tablet (US$),

December’2023

Figure 12-36: US – Prednisone Cost per Unit and Supply of 5mg Oral Tablet (US$),

December’2023

Figure 12-37: US – Prednisone Cost per Unit and Supply of 50mg Oral Tablet (US$),

December’2023

Figure 12-38: US – Prednisone Cost per Unit and Supply of 10mg Oral Tablet (US$),

December’2023

Figure 12-39: US – Prednisone Cost per Unit and Supply of 20mg Oral Tablet (US$),

December’2023

Figure 12-40: US – Vinblastine Cost per Unit and Supply (US$), December’2023

Figure 12-41: US – Dacarbazine Cost per Unit and Supply for 100mg Intravenous

Powder (US$), December’2023

Figure 12-42: US – Dacarbazine Cost per Unit and Supply for 200mg Intravenous

Powder (US$), December’2023

Figure 12-43: US – Erbitux Cost per Unit and Supply (US$), December’2023

Figure 12-44: US – Camptosar Cost per Unit and Supply (US$), December’2023

Figure 12-45: US – Irinotecan Cost per Unit and Supply (US$), December’2023

Figure 12-46: US – Cisplatin Cost per Unit and Supply for Intravenous Solution (US$),

December’2023

Figure 12-47: US – Paraplatin Cost per Unit and Supply (US$), December’2023

Figure 12-48: US – Carboplatin Cost per Unit and Supply (US$), December’2023

Figure 12-49: US – Adrucil Cost per Unit and Supply (US$), December’2023

Figure 12-50: US – Fluorouracil Cost per Unit and Supply (US$), December’2023

Figure 12-51: US – Leucovorin Cost of Supply of 100mg, 200mg, 350mg and 500mg

Injectable Powder (US$), December’2023

Figure 12-52: US – Leucovorin Cost per Unit and Supply of Injectable Solution (US$),

December’2023

Figure 12-53: US - Leucovorin Cost per Unit and Supply of 5mg Oral Tablet (US$),

December’2023

Figure 12-54: US - Leucovorin Cost per Unit and Supply of 10mg Oral Tablet (US$),

December’2023

Figure 12-55: US - Leucovorin Cost per Unit and Supply of 15mg Oral Tablet (US$),

December’2023

Figure 12-56: US - Leucovorin Cost per Unit and Supply of 25mg Oral Tablet (US$),

December’2023

Figure 12-57: US – Avastin Cost per Unit and Supply (US$), December’2023

Figure 12-58: US – Bevacizumab Biosimilar Cost per Unit and Supply for 4ml (US$),

December’2023

Figure 12-59: US – Bevacizumab Biosimilar Cost per Unit and Supply for 16ml (US$),

December’2023

Figure 12-60: US – Bevacizumab Biosimilar Alymsys Cost per Unit and Supply for 40ml

and 160ml (US$), December’2023

Figure 12-61: EU – Bevacizumab Biosimilar Vegzelma Cost per Supply (US$),

December’2023

Figure 12-62: US – Paclitaxel Cost per Unit and Supply (US$), December’2023

Figure 12-63: US – Paraplatin Cost per Unit and Supply (US$), December’2023

Figure 12-64: US – Carboplatin Cost per Unit and Supply (US$), December’2023

Figure 12-65: US – Tecentriq Cost per Unit and Supply (US$), November’2023

Figure 12-66: US – Gemzar Cost of Supply (US$), December’2023

Figure 12-67: US – Infugem Cost per Unit and Supply (US$), December’2023

Figure 12-68: US – Hycamtin Cost of Supply of Oral Capsule (US$), December’2023

Figure 12-69: US – Topotecan Cost of Supply of Intravenous Solution (US$),

December’2023

Figure 12-70: US – Keytruda Cost per Unit and Supply (US$), November’2023

Figure 12-71: EU – Keytruda Cost of Supply (US$), November’2023

Figure 12-72: US – Xeloda Cost per Unit and Supply (US$), November’2023

Figure 12-73: US – Capecitabine Cost per Unit and Supply of 150mg (US$),

November’2023

Figure 12-74: US – Capecitabine Cost per Unit and Supply of 500mg (US$),

November’2023

Figure 12-75: US – Adrucil Cost per Unit and Supply (US$), December’2023

Figure 12-76: US – Fluorouracil Cost per Unit and Supply (US$), December’2023

Figure 12-77: US – Cyclophosphamide Cost of Supply of Intravenous Powder (US$),

December’2023

Figure 12-78: US – Cyclophosphamide Cost per Unit and Supply of Intravenous

Solutions of Doses 1g/2ml, 2g/4ml, and 500mg/ml (US$), December’2023

Figure 12-79: US – Cyclophosphamide Cost per Unit and Supply of Intravenous

Solutions of Dose 200mg/ml (US$), December’2023

Figure 12-80: US – Cyclophosphamide Cost per Unit and Supply of Oral Capsule (US$),

December’2023

Figure 12-81: US – Cyclophosphamide Cost per Unit and Supply of Oral Tablet (US$),

December’2023

Figure 12-82: US – Adriamycin Cost of Supply of Intravenous Powder (US$),

December’2023

Figure 12-83: US – Adriamycin Cost per Unit and Supply of Intravenous Solution (US$),

December’2023

Figure 12-84: US – Doxorubicin Cost of Supply of Intravenous Powder (US$),

December’2023

Figure 12-85: US – Doxorubicin Cost per Unit and Supply of Intravenous Solution (US$),

December’2023

Figure 12-86: US – Paclitaxel Cost per Unit and Supply (US$), December’2023

Figure 12-87: US – Abraxane Cost per Unit and Supply (US$), December’2023

Figure 12-88: US – Cisplatin Cost per Unit and Supply for Intravenous Solution (US$),

December’2023

Figure 12-89: US – Paraplatin Cost per Unit and Supply (US$), December’2023

Figure 12-90: US – Carboplatin Cost per Unit and Supply (US$), December’2023

Figure 12-91: US – Eloxatin Cost per Unit and Supply (US$), December’2023

Figure 12-92: US – Oxaliplatin Cost per Unit and Supply of Intravenous Powder (US$),

December’2023

Figure 12-93: US – Oxaliplatin Cost per Unit and Supply of Intravenous Solution (US$),

December’2023

Figure 12-94: US – Gemzar Cost of Supply (US$), December’2023

Figure 12-95: US – Infugem Cost per Unit and Supply (US$), December’2023

Figure 12-96: US – Gemcitabine Cost of Supply of Intravenous Powder for Injection

(US$), December’2023

Figure 12-97: US – Gemcitabine Cost per Unit and Supply of 38mg/ml Intravenous

Solution (US$), December’2023

Figure 12-98: US – Gemcitabine Cost per Unit and Supply of 100mg/ml Intravenous

Solution (US$), December’2023

Figure 12-99: US – Alimta Cost of Supply (US$), December’2023

Figure 12-100: US – Pemfexy Cost per Unit and Supply (US$), December’2023

Figure 12-101: US – Pemetrexed Cost per Unit and Supply of Intravenous Powder for

Injection (US$), December’2023

Figure 12-102: US – Pemetrexed Cost per Unit and Supply of Intravenous Solution

(US$), December’2023

Figure 12-103: US – Ellence Cost per Unit and Supply of Intravenous Solution (US$),

December’2023

Figure 12-104: US – Epirubicin Cost per Unit and Supply of Intravenous Solution (US$),

December’2023

Figure 12-105: US – Herceptin Cost per Unit and Supply (US$), November’2023

Figure 12-106: US – Trastuzumab Biosimilar Cost per Unit and Supply (US$),

November’2023

Figure 12-107: US – Xeloda Cost per Unit and Supply (US$), November’2023

Figure 12-108: US – Capecitabine Cost per Unit and Supply of 150mg (US$),

November’2023

Figure 12-109: US – Capecitabine Cost per Unit and Supply of 500mg (US$),

November’2023

Figure 12-110: US – Adrucil Cost per Unit and Supply (US$), December’2023

Figure 12-111: US – Fluorouracil Cost per Unit and Supply (US$), December’2023

Figure 12-112: US – Cyclophosphamide Cost of Supply of Intravenous Powder (US$),

December’2023

Figure 12-113: US – Cyclophosphamide Cost per Unit and Supply of Intravenous

Solutions of Doses 1g/2ml, 2g/4ml and 500mg/ml (US$), December’2023

Figure 12-114: US – Cyclophosphamide Cost per Unit and Supply of Intravenous

Solutions of Dose 200mg/ml (US$), December’2023

Figure 12-115: US – Cyclophosphamide Cost per Unit and Supply of Oral Capsule (US$),

December’2023

Figure 12-116: US – Cyclophosphamide Cost per Unit and Supply of Oral Tablet (US$),

December’2023

Figure 12-117: US – Adriamycin Cost of Supply of Intravenous Powder (US$),

December’2023

Figure 12-118: US – Adriamycin Cost per Unit and Supply of Intravenous Solution (US$),

December’2023

Figure 12-119: US – Doxorubicin Cost of Supply of Intravenous Powder (US$),

December’2023

Figure 12-120: US – Doxorubicin Cost per Unit and Supply of Intravenous Solution

(US$), December’2023

Figure 12-121: US – Cisplatin Cost per Unit and Supply for Intravenous Solution (US$),

December’2023

Figure 12-122: US – Paclitaxel Cost per Unit and Supply (US$), December’2023

Figure 12-123: US – Libtayo Cost per Unit and Supply (US$), December’2023

Figure 12-124: US – Libtayo Cost per Unit and Supply (US$), December’2023

Figure 12-125: US – Cisplatin Cost per Unit and Supply for Intravenous Solution (US$),

December’2023

Figure 12-126: US – Paraplatin Cost per Unit and Supply (US$), December’2023

Figure 12-127: US – Carboplatin Cost per Unit and Supply (US$), December’2023

Figure 12-128: US – Eloxatin Cost per Unit and Supply (US$), December’2023

Figure 12-129: US – Oxaliplatin Cost per Unit and Supply of Intravenous Powder (US$),

December’2023

Figure 12-130: US – Oxaliplatin Cost per Unit and Supply of Intravenous Solution (US$),

December’2023

Figure 13-1: US – Phesgo Cost per Unit and Supply (US$), December’2023

Figure 13-2: EU – Phesgo Cost per Unit and Supply (US$), December’2023

Figure 13-3: US - Darzalex Cost per Unit and Supply (US$), November’2023

Figure 13-4: EU - Darzalex Cost per Unit and Supply (US$), December’2023

Figure 13-5: US – Kyprolis Cost per Unit and Supply (US$), November’2023

Figure 13-6: US – Dexamethasone Cost per Unit and Supply of 4mg/ml Injectable

Solution (US$), December’2023

Figure 13-7: US – Dexamethasone Cost per Unit and Supply of 10mg/ml Injectable

Solution (US$), December’2023

Figure 13-8: US – Dexamethasone Cost per Unit and Supply of 10mg/ml Preservative-Free Injectable Solution (US$), December’2023

Figure 13-9: US – Dexamethasone Cost per Unit and Supply of Oral Liquid (US$),

December’2023

Figure 13-10: US – Dexamethasone Cost per Unit and 100-Tablet Supply of 0.5mg, 1mg

and 6mg Oral Tablets (US$), December’2023

andlt;span style

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

Global Cancer Antibody Combinations Market Opportunity and Clinical Trials Insight 2028

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Need custom market research solution? We can help you with that too.

About us

Quick links

Contact us

Stay Connected